Bcl-2 Family Members As Prognostic Indicators in AML

References

• Kerr, J.F.R., Wylie, A.H. and Currie, A.R. (1972) “Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics”, Br. J. Cancer 26, 239–257.
   PubMed Web of Science ®Google Scholar
• Samali, A., Zhivotovsky, B., Jones, D., Nagata, S. and Orrenius, S. (1999) “Apoptosis: cell death defined by caspase activation”. Cell Death Differ. 6, 495–496.
   PubMed Web of Science ®Google Scholar
• Vaux, D.L. (1999) “Caspases and apoptosis—biology and terminology”, Cell Death Differ. 6, 493–494.
   PubMed Web of Science ®Google Scholar
• Blagosklonny, M.V. (2000) “Cell death beyond apoptosis”, Leukemia 14, 1502–1508.
   PubMed Web of Science ®Google Scholar
• Wyllie, A.H. and Golstein, P. (2001) “More than one way to go”, Proc. Natl Acad. Sci. USA 98, 11–13.
   PubMed Web of Science ®Google Scholar
• Joza, N., Susin, S.A., Daugas, E., et al., (2001) “Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death”, Nature 410, 549–554.
   PubMed Web of Science ®Google Scholar
• Wheatley, K., Burnett, A.K., Goldstone, A.H., et al., (1999) “A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial”, Br. J. Haematol. 107, 69–79.
   PubMed Web of Science ®Google Scholar
• Tsujimoto, Y., Gorham, J., Cossman, J., Jaffe, E. and Groce, C.M. (1985) “The t(14;18) chromosome translocations involved in B-cell neoplasma result from mistakes in VDJ joining”, Science 229, 1390–1393.
   PubMed Web of Science ®Google Scholar
• Suiston, J.E. and Horvitz, H.R. (1977) “Post-embryonic cell lineages of the nematode, Caenorhabditis elegans”, Dev. Biol. 56, 110–156.
   PubMed Web of Science ®Google Scholar
• Korsmeyer, S.J. (1992) “Bcl-2 initiates a new category of oncogenes: regulators of cell death”, Blood 80, 879–886.
   PubMed Web of Science ®Google Scholar
• Vaux, D., Cory, S. and Adams, J.M. (1988) “Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B-cells”, Nature 335, 440–442.
   PubMed Web of Science ®Google Scholar
• Said, J.W., Pinkus, G.S., Lones, M.A., Preston, M. and Shintaku, I.P. (1993) “Expression of bcl-2 oncogene protein in malignant lymphomas, including Hodgkin's Disease and non-Hodgkin's lymphomas of T-cell phenotype”, Appl. Immunohistochem. 1(2), 108–114.
   Google Scholar
• Pezzela, F., Tse, A.D.G., Cordell, J.L., Pulford, K.A.F. and Gatter, K.C. (1990) “Expression of the bcl-2 oncogene protein is not specific for the t(14;18) chromosomal translocation”, Am. J. Pathol. 137, 225–229.
   PubMed Web of Science ®Google Scholar
• Porwit-MacDonald, A., Ivory, K., Wilkinson, S., Wheatley, K., Wong, L. and Janossy, J. (1995) “Bcl-2 protein expression in normal human bone marrow precursors and in acute myelogenous leukaemia”, Leukemia 3, 23–28.
   Google Scholar
• Yin, X.M., Oltvai, Z.N. and Korsmeyer, S.J. (1994) “BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax”, Nature 369, 321–323.
   PubMed Web of Science ®Google Scholar
• Kroemer, G. (1997) “The proto-oncogene bcl-2 and its role in regulating apoptosis”, Nat. Med. 3, 614–620.
   PubMed Web of Science ®Google Scholar
• Adams, J.M. and Cory, S. (1998) “The bcl-2 protein family: arbiters of cell survival”, Science 281, 1322–1326.
   PubMed Web of Science ®Google Scholar
• Huang, D.C.S. and Strasser, A. (2000) “BH3 only proteins—essential initiators of apoptotic cell death”, Cell 103, 839–842.
   PubMed Web of Science ®Google Scholar
• Korsmeyer, S.J., Gross, A., Harada, H., et al., (1999) “Death and Survival Signals determine active/inactive conformations of Pro-apoptotic BAX, BAD, and BID Molecules”, Cold Spring Harbor Symp. Quant. Biol. 64, 343–350.
   PubMedGoogle Scholar
• Gross, A., McDonnell, J.M. and Korsmeyer, S.J. (1999) “BCL-2 family members and the mitochondria in apoptosis”, Genes Dev. 13, 1899–1911.
   PubMed Web of Science ®Google Scholar
• Chao, D.T. and Korsmeyer, S.J. (1998) “Bcl-2 family: regulators of cell death”, Ann. Rev. Immunol. 16, 395–419.
   PubMed Web of Science ®Google Scholar
• Oltavi, Z., Milliman, C.L. and Korsmeyer, S.J. (1993) “Bcl-2 heterodimerizes in vivo with conserved homolog, bax, that accelerates programmed cell death”, Cell 74, 609–619.
   PubMed Web of Science ®Google Scholar
• Oltvai, Z.N. and Korsmeyer, S.J. (1994) “Checkpoints of duelling dimers foil death wishes”, Cell 79, 189–192.
   PubMed Web of Science ®Google Scholar
• Matsuyama, S., Xu, Q., Velours, J. and Reed, J.C. (1998) “The Mitochondrial FOF1-ATPase proton pump is required for function of the proapoptotic protein Bax in yeast and mammal cells”, Mol. Cell 3, 327–336.
   Web of Science ®Google Scholar
• Fesik, S.W. (2000) “Insights into programmed cell death through structural biology”, Cell 103, 273–282.
   PubMed Web of Science ®Google Scholar
• Wei, M.C., Zong, W.-X., Cheng, E.H.Y., et al., (2000) “tBID, a membrane-targeted death ligand, oligomerises BAK to release cytochrome c”, Genes Dev. 14, 2060–2071.
   PubMed Web of Science ®Google Scholar
• Wei, M.C., Zong, W.-X., Cheng, E.H.Y., et al., (2001) “Proapoptotic Bax and Bak: a requisite gateway to mitochondrial dysfunction and death”, Science 292, 727–730.
   PubMed Web of Science ®Google Scholar
• Green, D.R. and Reed, J.C. (1998) “Mitochondria and apoptosis”, Science 281, 1309–1312.
   PubMed Web of Science ®Google Scholar
• Costantini, P., Jacotot, E., Decaudin, D. and Kroemer, G. (2000) “Mitochondrion as a novel target of anticancer therapy”, J. Natl Cancer Inst. 92, 1042–1053.
   PubMed Web of Science ®Google Scholar
• Ruffolo, S.C., Breckenridge, D.G., Nguyen, M., et al., (2000) “BID-dependent and BID-independent pathways for BAX insertion into mitochondria”, Cell Death Differ. 7, 1101–1108.
   PubMed Web of Science ®Google Scholar
• Antonsson, B., Montessuit, S., Sanchez, B. and Martinou, J.C. (2001) “Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells”, J. Biol. Chem. 276, 11615–11623.
   PubMed Web of Science ®Google Scholar
• Jia, L., Macey, M.G., Yin, Y., Newland, A.C. and Kelsey, S.M. (1999) “Subcellular distribution and redistribution of Bcl-2 family proteins in human leukemia cells undergoing apoptosis”, Blood 93(7), 2353–2359.
   PubMed Web of Science ®Google Scholar
• Cai, Z., Lin, M., Wuchter, C., et al., (2001) “Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation”, Leukemia 15, 567–574.
   PubMed Web of Science ®Google Scholar
• Kluck, R.M., Bossy-Wetzel, E., Green, D.R. and Newmeyer, D.D. (1997) “The release of cytochrome c from mitochondria: a primary site for bcl-2 regulation of apoptosis”. Science 275, 1132–1136.
   PubMed Web of Science ®Google Scholar
• Yang, J., Xuesong, L., Bhalla, K., et al., (1997) “Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked”, Science 275, 1129–1132.
   PubMed Web of Science ®Google Scholar
• Liu, X., Kim, C.N., Pohl, J. and Wang, X. (1996) “Purification and characterization of an interleukin-1beta-converting enzyme family protease that activates cysteine protease P32 (CPP32)”, J. Biol. Chem. 271, 13371–13376.
   PubMed Web of Science ®Google Scholar
• Zou, H., Henzel, W.J., Liu, X., Lutschg, A. and Wang, X. (1997) “Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3”, Cell 90, 405–413.
   PubMed Web of Science ®Google Scholar
• Liu, X., Zou, H., Slaughter, C. and Wang, X. (1997) “DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis”, Cell 89, 175–184.
   PubMed Web of Science ®Google Scholar
• Zamzami, N., Susin, S.A., Marchetti, P., et al., (1996) “Mitochondrial control of nuclear apoptosis”, J. Exp. Med. 183, 1533–1544.
   PubMed Web of Science ®Google Scholar
• Susin, S.A., Zamzami, N., Castedo, M., et al., (1996) “Bcl-2 inhibits the mitochondrial release of an apoptogenic protease”, J. Exp. Med. 184, 1331–1341.
   PubMed Web of Science ®Google Scholar
• Jurgensmeier, J.M., Xie, Z., Deveraux, Q., Ellerby, L., Bredesen, D. and Reed, J.C. (1998) “Bax directly induces release of cytochrome c from isolated mitochondria”, Proc. Natl Acad. Sci. USA 95, 4997–5002.
   PubMed Web of Science ®Google Scholar
• Vander Heiden, M.G., Chandel, N.S., Williamson, E.K., Schumacker, P.T., Thompson, C.B., (1997) “Bcl-x1. regulates the membrane potential and volume homeostasis of mitochondria”, Cell 91, 627–637.
   PubMed Web of Science ®Google Scholar
• Johnson, D.E. (2000) “Programmed cell death regulation: basic mechanisms and therapeutic opportunities”, Leukemia 14, 1340–1344.
   PubMed Web of Science ®Google Scholar
• Fadeel, B., Hassan, Z., Hellstrom-Lindberg, M., et al., (1999) “Cleavage of bcl-2 is an early event in chemotherapy-induced apoptosis of human myeloid leukaemia cells”, Leukaemia 13, 719–728.
   PubMed Web of Science ®Google Scholar
• Datta, R., Banach, D., Kojima, H., et al., (1996) “Activation of the CPP32 protease in apoptosis induced by 1-b-D arabinofuranosylcytosine and other DNA-damaging agents”, Blood 88, 1936–1943.
   PubMed Web of Science ®Google Scholar
• Efferth, T., Fabry, U. and Osieka, R. (1997) “Apoptosis and resistance to daunorubicin in human leukaemic cells”, Leukaemia 11, 1180–1186.
   PubMed Web of Science ®Google Scholar
• Blagosklonny, M.V., Somasundaram, K., Wu, G.S. and El- Deiry, W.S. (1997) “Wild type p53 is not sufficient for serum starvation-induced apoptosis in cancer cells but accelerates apoptosis in sensitive cells”, Int. J. Oncol 11, 1165–1170.
   PubMed Web of Science ®Google Scholar
• Wuchter, C., Karawajew, L., Ruppert, V., et al., (1999) “Clinical significance of CD95, bcl-2 and bax expression in adult de novo acute leukemia in context of p-glycoprotein function, maturational stage and cytogenetics”, Leukemia 13, 1943–1953.
   PubMed Web of Science ®Google Scholar
• Los, M., Herr, I., Friesen, C., et al., (1997) “Cross resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases)”, Blood 90, 3118–3129.
   PubMed Web of Science ®Google Scholar
• Meinhardt, G., Roth, J., Totok, G., et al., (1999) “Signalling defect in the activation of caspase-3 and PKC delta in human TUR leukaemia cells is associated with resistance to apoptosis”, Exp. Cell Res. 247, 529–533.
   Web of Science ®Google Scholar
• Hannun, Y.A. (1997) “Apoptosis and the dilemma of cancer chemotherapy”, Blood 89, 1845–1853.
   PubMed Web of Science ®Google Scholar
• Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. and Reed, J.C. (1993) “Bcl-2 gene hypomethylation and high level expression in B-cell chronic lymphocytic leukaemia”, Blood 82, 1820–1828.
   PubMed Web of Science ®Google Scholar
• Dole, M., Nunez, G., Merchant, A.K., et al., (1994) “Bcl-2 inhibits chemotherapy-induced apoptosis in neuroblastoma”, Cancer Res. 54, 3253–3259.
   PubMed Web of Science ®Google Scholar
• Eliopoulos, A.G., Kerr, D.J., Herod, J., et al, (1995) “The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2”. Oncogene 11, 1217–1228.
   PubMed Web of Science ®Google Scholar
• Reed, J.C. (1994) “Bcl-2 and the regulation of programmed cell death”, J. Cell Biol 124, 1–6.
   PubMed Web of Science ®Google Scholar
• White, E. (1996) “Life, death, and the pursuit of apoptosis”, Genes Dev. 10, 1–15.
   PubMed Web of Science ®Google Scholar
• Miyashita, T. and Reed, J.C. (1992) “Bcl-2 gene transfer increases relative resistance of S49.1 and WEH 17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs”, Cancer Res. 52, 5407–5411.
   PubMed Web of Science ®Google Scholar
• Miyashita, T. and Reed, J.C. (1993) “Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line”, Blood 81, 151–157.
   PubMed Web of Science ®Google Scholar
• Walton, W.I., Whysong, D., O'Connor, P.M., Hockenberry, D., Korsmeyer, S.J. and Kohn, K.W. (1993) “Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis”, Cancer Res. 53, 151–157.
   Web of Science ®Google Scholar
• Kamesaki, S., Kamesaki, H., Jorgensen, T.J., et al., (1993) “Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair”, Cancer Res. 53, 4251–4256.
   PubMed Web of Science ®Google Scholar
• Tang, C, Willingham, M.C., Reed, J.C., et al., (1994) “High levels of p26 bcl-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells”, Leukemia 8, 1960–1969.
   PubMed Web of Science ®Google Scholar
• Reed, J.C. (1995a) “Bcl-2 family proteins: regulators of chemoresistance in cancer”, Toxicol. Lett. 82/83, 155–158.
   Web of Science ®Google Scholar
• Reed, J.C. (1995b) “Bcl-2: Prevention of apoptosis as a mechanism of drug resistance”, Hematol. Oncol. Clin. N. Am. 9, 451–473.
   PubMed Web of Science ®Google Scholar
• Sachs, L. and Lotem, J. (1993) “Regulation by bcl-2, c-myc and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukaemic cells”, Cell Growth Differ. 4, 41–47.
   PubMedGoogle Scholar
• Lotem, J. and Sachs, L. (1994) “Control of sensitivity to induction of apoptosis in myeloid leukaemic cells by differentiation and bcl-2 dependent and independent pathways”, Cell Growth Differ. 5, 321–327.
   PubMedGoogle Scholar
• Kitada, S., Takayama, S., De Riel, K., Tanaka, S. and Reed, J.C. (1994) “Reversal of chemoresistance of lymphoma cells by antisense-mediated reduction of bcl-2 gene expression”, Antisense Res. Dev. 4, 71–79.
   PubMedGoogle Scholar
• Campos, L., Sabido, O., Rouault, J.P. and Guyotat, D. (1994) “Effects of bcl-2 antisense oligodeoxynucleotides on in vitro proliferation and survival of normal marrow progenitors and leukaemic cells”, Blood 84, 595–600.
   PubMed Web of Science ®Google Scholar
• Berchem, G.J., Bosseler, M., Sugars, L.Y., Voeller, H.J., Zeitlin, S. and Gelmann, E.P. (1995) “Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells”, Cancer Res. 55, 735–738.
   PubMed Web of Science ®Google Scholar
• Teixeira, C., Reed, J.C. and Pratt, M.A.C. (1995) “Estrogen promotes chemotherapuetic drug resistance by a mechanism involving bcl-2 proto-oncogene expression in human breast cancer cells”, Cancer Res. 55, 3902–3907.
   PubMed Web of Science ®Google Scholar
• Bradbury, D.A., Zhu, Y.M. and Russell, N.H. (1994) “Regulation of bcl-2 expression and apoptosis in acute myeloblastic leukaemia cells by granulocyte-macrophage colony-stimulating factor”, Leukemia 8, 786–791.
   PubMed Web of Science ®Google Scholar
• Komblau, S.M., Thall, P., Estrov, Z., et al., (1999) “The prognostic impact on bcl-2 protein expression in acute myelogenous leukemia varies with cytogenetics”, Clin. Cancer Res. 5, 1758–1766.
   PubMed Web of Science ®Google Scholar
• Hu, Z., Minden, M. and McCulloch, E.A. (1995) “Direct evidence for the participation of bcl-2 in the regulation by retinole acid of the ARA-C sensitivity of leukemic stem cells”, Leukemia 9,1667–1673.
   PubMed Web of Science ®Google Scholar
• Andreeff, M., Jiang, S., Zhang, X., et al., (1999) “Expression of Bcl-2 related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid”, Leukemia 13, 1881–1892.
   PubMed Web of Science ®Google Scholar
• Cotter, F.E., Johnston, P., Hall, P., et al., (1994) “Antisense oligonucleotides suppresses B-cell lymphoma growth in a SCID-hu mouse model”, Oncogene 9, 3049–3055.
   PubMed Web of Science ®Google Scholar
• Reed, J.C., Kitada, S., Takayama, S. and Miyashita, T. (1994) “Regulation of chemoresistance by the bcl-2 oncoprotein in non Hodgkin's lymphoma and lymphocytic leukemia cell lines”, Ann. Oncol. 5, 61–65.
   PubMed Web of Science ®Google Scholar
• Keith, F.J., Bradbury, D.A., Zhu, Y.M. and Russell, N.H. (1995) “Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts to Ara-C”, Leukemia 9, 131–138.
   PubMed Web of Science ®Google Scholar
• Konopleva, M., Tari, A.M., Estrov, Z., et al., (2000) “Liposomal bcl-2 antisense oligonucleotides enhance proliferation, sensitize acute myeloid leukemia to cytosine- arabinoside, and induce apoptosis independent of other anti-apoptotic proteins”, Blood 84, 1415–1420.
   Google Scholar
• Smith, M.R., Abubakar, Y., Mohammad, R., Xie, T., Hamdan, M. and al Katib, A. (1995) “Antisense oligodeoxyribonucleotide down-regulation of bcl-2 gene expression inhibits growth of the low-grade non-Hodgkin's lymphoma cell line WSU-FSCCL”, Cancer Gene Ther. 2, 207–212.
   PubMed Web of Science ®Google Scholar
• Campos, L., Rouault, J.P., Sabido, O., et al., (1993) “High expression of bcl-2 protein in acute myeloid leukaemia cells is associated with poor response to chemotherapy”, Blood 81, 3091–3096.
   PubMed Web of Science ®Google Scholar
• Maung, Z.T., Mac Lean, F.R., Reid, M.M., et al., (1994) “The relationship between bcl-2 expression and response to chemotherapy in acute leukaemia”, Br. J. Haematol. 88, 105–109.
   PubMed Web of Science ®Google Scholar
• Bradbury, D.A. and Russell, N.H. (1995) “Comparative quantitative expression of bcl-2 by normal and leukaemic myeloid cells”, Br. J. Haematol. 91, 374–379.
   PubMed Web of Science ®Google Scholar
• Lauria, F., Raspadori, D., Rondelli, D., et al., (1997) “High bcl-2 expression in acute myeloid leukaemia cells correlates with CD34 positivity and complete remission rate”, Leukemia 11, 2075–2078.
   PubMed Web of Science ®Google Scholar
• Karakas, T., Maurer, U., Weidmann, E., Miething, C.C., Hoelzer, D. and Bergmann, L. (1998) “High expression of bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukaemia”, Ann. Oncol. 9, 159–165.
   PubMed Web of Science ®Google Scholar
• Chomienne, C., Barbey, S., Balitrand, N., Degos, L. and Sachs, K. (1992) “Regulation of bcl-2 and cell death by alltrans retinoic acid in acute promyelocytic cells”, Proc. Am. Assoc. Cancer Res. 33, 41.
   Google Scholar
• Bradbury, D.A., Aldington, S., Zhu, Y.M. and Russell, N.H. (1996) “Down-regulation of bcl-2 in AML blasts by all-trans retinoic acid and its relationship to CD34 antigen expression”, Br. J. Haematol. 94, 671–675.
   PubMed Web of Science ®Google Scholar
• Reed, J.C., Cuddy, M., Haldar, S., et al., (1990) “Bcl-2 mediated tumorigenicity of a human T-lymphoid cell line: synergy with Myc and inhibition by bcl-2 anti-sense”, Proc. Natl Acad. Sci. USA 87, 3660–3664.
   PubMed Web of Science ®Google Scholar
• Fenaux, P., Castaigne, S., Dombret, H., et al., (1992) “All-trans-retinoic acid followed by intensive chemotherapy gives a high complete remission rate and may porolong remissions in newly diagnosed acute promyelocytic leukemia: a pilot study on 26 cases”, Blood 80, 2176–2181.
   PubMed Web of Science ®Google Scholar
• Lotem, J. and Sachs, L. (1995) “Regulation of bcl-2, bcl-x1 and bax in the control of apoptosis by cytokines and dexamethasone”, Cell Growth Differ. 6, 647–653.
   PubMedGoogle Scholar
• Fontana, J.A., Sun, R.J., Rishi, A.K., et al., (1998) “Overexpression of bcl-2 or bcl-x1, fails to inhibit apoptosis mediated by a novel retinoid”, Oncol. Res. 10, 313–324.
   PubMed Web of Science ®Google Scholar
• Korsmeyer, S.J., Shutter, J.R., Veis, D.J., et al., (1993) “Bcl-2/bax: a rheostat that regulates an anti-oxidant pathway and cell death”, Semin. Cancer Biol. 4, 327–332.
   PubMed Web of Science ®Google Scholar
• Stoetzer, O.J., Nussler, V., Darsow, M., et al., (1996) “Association of bcl-2, bax, bcl-xL and interleukin-1 beta- converting enzyme expression with initial response to chemotherapy in acute myeloid leukemia”. Leukemia 10(Suppl. 3), S18–S22.
   PubMedGoogle Scholar
• Deng, G., Lane, C., Kornblau, S., et al., (1998) “Ratio of bcl-xshort to bcl-xlong is different in good- and poor-prognosis subsets of acute myeloid leukaemia”, Mol. Med 4, 158–164.
   PubMed Web of Science ®Google Scholar
• Hogarth, L.A. and Hall, A.G. (1999) “Increased BAX expression is associated with an increased risk of relapse in childhood acute lymphoblastic leukaemia”, Blood 93, 2671–2678.
   PubMed Web of Science ®Google Scholar
• Salomons, G.S., Smets, L.A., Verwijs-Janssen, M., et al., (1999) “Bcl-2 family members in childhood acute lymphoblastic leukemia: relationships with features at presentation, in vitro and in vivo drug response and long-term clinical outcome”, Leukemia 13, 1574–1580.
   PubMed Web of Science ®Google Scholar
• Prokop, A., Wieder, T., Sturm, I., et al., (2000) “Relapse in childhood ALL is associated with a decrease of the bax/bcl-2 ratio and loss of spontaneous caspase-3 processing in vivo”, Leukemia 14, 1606–1613.
   PubMed Web of Science ®Google Scholar
• Reed, J.C. (1997) “Double identify for proteins of the bcl-2 family”, Nature 387, 773–776.
   PubMed Web of Science ®Google Scholar
• Shinoura, N., Yoshida, Y., Nishimura, M., Muramatsu, Y., et al., (1999) “Expression level of Bcl-2 determines anti- or proapoptotic function”, Cancer Res. 59, 4119–4128.
   PubMed Web of Science ®Google Scholar
• Cheng, E.H., Kirsch, D.G., Clem, R.J., et al., (1997) “Conversion of Bcl-2 to a Bax-like death effector by caspases”, Science 278, 1966–1968.
   PubMed Web of Science ®Google Scholar
• Fujita, N. and Tsuruo, T. (1998) “Involvement of bcl-2 cleavage in the acceleration of VP-16-induced U937 cell apoptosis”, Biochem. Biophys. Res. Commun. 246, 484–488.
   PubMed Web of Science ®Google Scholar
• Grangirard, D., Studer, E., Monney, L., et al., (1998) “Alphaviruses induce apoptosis in bcl-2-overexpressing cells: evidence for a caspase-mediated, proteolytic inactivation of bcl-2”, EMBO J. 17, 1268–1278.
   PubMed Web of Science ®Google Scholar
• Clem, R.J., Cheng, E.H.-Y., Karp, C.L., et al., (1998) “Modulation of cell death by Bcl-X1 through caspase interaction”, Proc. Natl Acad. Sci. USA 95, 554–559.
   PubMed Web of Science ®Google Scholar
• Hunter, T. (2000) “Signaling-2000 and beyond”, Cell 100, 113–127.
   PubMed Web of Science ®Google Scholar
• Deng, X., Kornblau, S.M., Ruvolo, P.P. and Stratford May, W. (2000) “Regulation of Bcl-2 phosphorylation and potential significance for leukemic cell chemoresistance”, J. Natl Cancer Inst. Monogr. 28, 30–37.
   Google Scholar
• Maundrell, K., Antonsson, B., Magnenat, E., et al., (1997) “Bcl-2 undergoes phosphorylation by c-Jun N-terminal kinase/stress-activated protein kinases in the presence of the constitutively active GTP-binding protein Rac1”, J. Biol. Chem. 272, 25238–25242.
   PubMed Web of Science ®Google Scholar
• Kornblau, S.M., Vu, H.T., Ruvolo, P., et al., (2000) “BAX and PKCalpha modulate the prognostic impact of BCL2 expression in acute myelogenous leukemia”, Clin. Cancer Res. 6, 1401–1409.
   PubMed Web of Science ®Google Scholar
• Blagosklonny, M.V. (2001) “Unwinding the loop of Bcl-2 phosphorylation”, Leukemia 15, 869–874.
   PubMed Web of Science ®Google Scholar
• Chang, B.S., Minn, A.J., Muchmore, S.W., Fesik, S.W. and Thompson, C.B. (1997) “Identification of a novel regulatory domain in Bcl-X(1 and Bcl-2”, EMBO J. 16, 968–977.
   PubMed Web of Science ®Google Scholar
• Fang, G., Chang, B.S., Kim, C.N., Perkins, C., Thompson, C.B. and Bhalla, K.N. (1998) ““Loop” domain is necessary for raxol induced mobility shift and phosphorylation of Bcl-2 as well as for inhibiting raxol-induced cytosolic accumulation of cytochrome c and apoptosis”, Cancer Res. 58, 3202–3208.
   PubMed Web of Science ®Google Scholar
• Ito, T., Deng, X., Carr, B. and Way, W.S. (1997) “Bcl-2 phosphorylation required for anti-apoptosis function”, J. Biol. Chem., 272 11671–11673.
   PubMed Web of Science ®Google Scholar
• Basu, A. and Haldar, S. (1998) “Microtubule-damaging drugs triggered bcl2 phosphorylation-requirement of phosphorylation on both serine-70 and serine-87 residues of bcl-2 protein”, Int. J. Oncol. 13, 659–664.
   PubMed Web of Science ®Google Scholar
• Haldar, S., Basu, A. and Croce, C.M. (1997) “Bcl-2 is the guardian of microtubule integrity”, Cancer Res. 57, 229–233.
   PubMed Web of Science ®Google Scholar
• Hu, Z.-B., Minden, M.D. and McCulloch, E.A. (1998) “Phosphorylation of BCL-2 after exposure of human leukemic cells to retinoic acid”, Blood 92, 1768–1775.
   PubMed Web of Science ®Google Scholar
• Müllauer, L., Gruber, P., Sebinger, D., Buch, J., Wohlfart, S. and Chott, A. (2001) “Mutations in apoptosis genes: a pathogenetic factor for human disease”, Mutat. Res. 488, 211–231.
   PubMed Web of Science ®Google Scholar
• Meijerink, J.P.P., Mensink, E.J.B.M., Wang, K., et al., (1998) “Hematopoietic malignancies demonstrate loss-of-function mutations of BAX”, Blood 91, 2991–2997.
   PubMed Web of Science ®Google Scholar
• Martini, M., D'Alo, F., Pierconti, F., et al, (2000) “Bax mutations are an infrequent event in indolent lymphomas and in mantle cell lymphoma”, Haemntologica 85, 1019–1023.
   PubMed Web of Science ®Google Scholar
• Molenaar, J.J., Bénédicte, G., Chambon-Pautas, C., et al., (1998) “Microsatellite instability and frameshift mutations in BAX and transforming growth factor-β RII genes are very uncommon in acute lymphoblastic leukemia in vivo but not in cell lines”, Blood 92, 230–233.
   PubMed Web of Science ®Google Scholar
• Rampino, N., Yamamoto, H., Inov, Y., Li, Y., Sawai, H., Reed, J.C. and Perucho, M. (1997) “Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype”, Science 275, 967–969.
   PubMed Web of Science ®Google Scholar
• Inov, Y., Yamamoto, H., Krajewski, S., Reed, J.C. and Perucho, M. (2000) “Mutational inactivation of the proapoptotic gene BAX confers selective advantage during tumor clonal evolution”, Proc. Natl Acad. Sci. USA 97, 10872–10877.
   PubMed Web of Science ®Google Scholar
• Cho, S., Hahm, J.H. and Hong, Y.S. (2001) “Analysis of p53 and BAX mutations, loss of heterozygosity, p53 and BCL2 expression and apoptosis in basal cell carcinoma in Korean patients”, Br. J. Dermatol. 144, 841–848.
   PubMed Web of Science ®Google Scholar
• Sedlak, T.W., Oltvai, Z.N., Yang, E. et al., (1995) “Multiple Bcl-2 family members demonstrate selective dimerisations with Bax”, Proc. Natl Acad. Sci. USA 92, 7834–7838.
   PubMed Web of Science ®Google Scholar
• Haldar, S., Basu, A. and Croce, C.M. (1998) “Serine-70 is one of the critical sites for drug induced Bcl-2 phosphorylation in cancer cells”, Cancer Res. 58, 1609–1615.
   PubMed Web of Science ®Google Scholar
• Breitschopf, K., Haendeler, J., Malchow, P., Zeiher, A.M. and Dimmeier, S. (2000) “Posttranslational modification of Bcl-2 facilitates its proteasome-dependent degradation: molecular characterization of the involved signaling pathway”, Mol Cell Biol 5, 1886–1896.
   Web of Science ®Google Scholar
• Matolcsy, A., Casali, P., Warnke, R.A. and Knowles, D.M. (1996) “Morphologic transformation of follicular lymphoma is associated with somatic mutation of the translocated Bcl-2 gene”, Blood 88, 3937–3944.
   PubMed Web of Science ®Google Scholar
• Matolcsy, A., Warnke, R.A. and Knowles, D.M. (1997) “Somatic mutations of the translocated bcl-2 gene are associated with morphologic transformation of follicular lymphoma to diffuse large-cell lymphoma”, Ann. Oncol 8, 119–122.
   PubMed Web of Science ®Google Scholar